Silexion Therapeutics Corp (SLXN)
- Previous Close
0.9500 - Open
0.9400 - Bid 0.6671 x 200
- Ask 1.2100 x 200
- Day's Range
0.9358 - 0.9699 - 52 Week Range
0.2070 - 13.5580 - Volume
13,777 - Avg. Volume
4,465,977 - Market Cap (intraday)
8.26M - Beta (5Y Monthly) 0.06
- PE Ratio (TTM)
-- - EPS (TTM)
-26.3600 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
5.00
Silexion Therapeutics Corp, a biopharmaceutical company, discovers and develops RNA interference (RNAi)-based cancer drugs and delivery systems to treat malignant solid tumors. The company engages in the treatment of solid tumors through its proprietary LODER delivery platform. Its products comprise SiG12D-LODER that has completed pre-clinical studies and an open label Phase I clinical trial for the treatment of pancreatic cancer; Prostate-LODER, which is in pre-clinical studies for the treatment of prostate cancer; and GBM-LODER that is in pre-clinical studies to target Glioblastoma Multiform, a malignant primary brain tumor. Silexion Therapeutics Corp has collaboration with Evonik Corporation for the development of an advanced siRNA formulation to enhance cancer treatment. The company was founded in 2008 and is headquartered in Jerusalem, Israel.
silexion.comRecent News: SLXN
View MorePerformance Overview: SLXN
Trailing total returns as of 5/16/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: SLXN
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SLXN
View MoreValuation Measures
Market Cap
8.39M
Enterprise Value
11.69M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-193.54%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-16.44M
Diluted EPS (ttm)
-26.3600
Balance Sheet and Cash Flow
Total Cash (mrq)
1.19M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.41M